BrainsWay Ltd. (BWAY) Research

BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Market snapshot

Symbol
BWAY
Price
$14.89
Day change
+3.33%
Market cap
$582.6M
P/E ratio
62.86x
52-week range
5.42-17.352
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months
Analyst price target
$16.00

Peer companies

  • Cerus Corporation (CERS)
  • CVRx, Inc. (CVRX)
  • Delcath Systems, Inc. (DCTH)
  • 908 Devices Inc. (MASS)
  • NeuroPace, Inc. (NPCE)
  • RxSight, Inc. (RXST)
  • Senseonics Holdings, Inc. (SENS)
  • Sight Sciences, Inc. (SGHT)

Recent insider activity

  • Mitrany Rayten Michal Ety — S-Sale (10000 shares) on 2026-05-25
  • Mitrany Rayten Michal Ety — S-Sale (7980 shares) on 2026-05-26
  • Mitrany Rayten Michal Ety — M-Exempt (17500 shares) on 2026-05-20
  • Mitrany Rayten Michal Ety — F-InKind (6080 shares) on 2026-05-20
  • Mitrany Rayten Michal Ety — M-Exempt (10000 shares) on 2026-05-19

Open BrainsWay Ltd. (BWAY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.